Show simple item record

dc.contributor.authorGrande, E
dc.contributor.authorGlen, H
dc.contributor.authorAller, J
dc.contributor.authorArgenziano, G
dc.contributor.authorLamas, MJ
dc.contributor.authorRuszniewski, P
dc.contributor.authorZamorano, JL
dc.contributor.authorEdmonds, K
dc.contributor.authorSarker, S
dc.contributor.authorStaehler, M
dc.contributor.authorLarkin, J
dc.date.accessioned2018-02-16T11:43:37Z
dc.date.issued2017-12
dc.identifier.citationExpert opinion on drug safety, 2017, 16 (12), pp. 1413 - 1426
dc.identifier.issn1474-0338
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1211
dc.identifier.eissn1744-764X
dc.identifier.doi10.1080/14740338.2017.1380624
dc.description.abstractIntroduction There are several second-line treatment options for patients with renal cell carcinoma after first-line failure of a tyrosine kinase inhibitor, especially with the recent approvals of cabozantinib, nivolumab, and the lenvatinib plus everolimus combination. A lack of reliable biomarkers and an overall lack of prospective head-to-head comparisons make it a challenge to choose a second-line treatment in the clinic. Areas covered: In this review/meta-opinion, we describe the safety profile of the lenvatinib plus everolimus combination in renal cell carcinoma. The combination of lenvatinib plus everolimus has achieved the highest rates of objective responses and the longest progression free and overall survival in cross-comparison trials. At the same time, the safety profile of this combination, including the rate of total and severe adverse events, the percentage of dose reductions required, and the rate of treatment discontinuation, was less favorable compared with available monotherapy options, suggesting that better management could help to maximize the activity of this combination while protecting patients from undue harm. Expert opinion: Herein, we aim to postulate multidisciplinary recommendations on the advice to offer to patients and caregivers before starting treatment and how to manage the combination from the perspective of daily clinical practice.
dc.formatPrint-Electronic
dc.format.extent1413 - 1426
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectCarcinoma, Renal Cell
dc.subjectKidney Neoplasms
dc.subjectPhenylurea Compounds
dc.subjectQuinolines
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDisease-Free Survival
dc.subjectSurvival Rate
dc.subjectDose-Response Relationship, Drug
dc.subjectEverolimus
dc.titleRecommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14740338.2017.1380624
rioxxterms.licenseref.startdate2017-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfExpert opinion on drug safety
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume16
pubs.embargo.termsNot known
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record